RB1 and triple-negative breast carcinoma: This therapeutic approach might become even more significant when the RB pathway is functionally disrupted in many aggressive human cancers, including triple-negative breast cancer (TNBC), which represents the most aggressive subtype of breast cancer with limited treatment options15–17.